# Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
Canonical URL: https://biopharmsignal.com/news/MRUS/genmab-announces-completion-of-tender-offer-for-outstanding-common-shares-of-merus-n-v-and-commencement-of-subsequent-offering-period
Ticker: MRUS
Company: Merus
Source: Merus
Published: 2025-12-12 07:54 EST
Original Source URL: https://ir.merus.nl
## Summary

Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio Transaction anticipated to be accretive to Genmab’s EBITDA by end of 2029 COPENHAGEN, Denmark; December 12, 2025 – Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced

## Article Body
Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio Transaction anticipated to be accretive to Genmab’s EBITDA by end of 2029 COPENHAGEN, Denmark; December 12, 2025 – Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced
## Recent Company News
- 2025-12-12 07:54 EST — [Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period](https://biopharmsignal.com/news/MRUS/genmab-announces-completion-of-tender-offer-for-outstanding-common-shares-of-merus-n-v-and-commencement-of-subsequent-offering-period) — Source: Merus
- 2025-11-17 12:15 EST — [Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab](https://biopharmsignal.com/news/MRUS/merus-and-halozyme-enter-global-collaboration-and-license-agreement-to-develop-subcutaneous-formulation-of-petosemtamab) — Source: Merus
- 2025-10-24 14:00 EST — [Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety](https://biopharmsignal.com/news/MRUS/merus-interim-data-on-petosemtamab-in-metastatic-colorectal-cancer-demonstrates-monotherapy-activity-and-robust-response-rate-in-combination-with-folfox-folfiri-with-well-tolerated-safety) — Source: Merus
- 2025-10-14 11:30 EST — [Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics](https://biopharmsignal.com/news/MRUS/merus-announces-publication-of-an-abstract-on-petosemtamab-in-metastatic-colorectal-cancer-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics) — Source: Merus
- 2025-10-13 16:00 EST — [Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics](https://biopharmsignal.com/news/MRUS/merus-announces-petosemtamab-in-metastatic-colorectal-cancer-abstract-selected-for-plenary-session-oral-presentation-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics) — Source: Merus
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)